GlassScriptPhysician profile
David F Henderson
NPI 1578582912
$10,437.02
in general payments reported to CMS, 2019-2025
56 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,673 · 2022: $1,941 · 2023: $2,629 · 2024: $2,395 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,822.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,284.78 | 2021-2025 | |
| Novo Nordisk INC | $1,204.04 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,187.80 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,160.55 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $680.81 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $596.92 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $489.15 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $420.77 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $247.44 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $241.91 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.00 | 2021-2025 | Jardiance |
| Preventric Diagnostics, INC. | $222.85 | 2021 | |
| Phathom Pharmaceuticals, INC. | $204.94 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $171.75 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $168.53 | 2022-2025 | Rexulti |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $130.30 | 2021-2025 | Trintellix |
| Dexcom, INC. | $109.95 | 2022-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $108.68 | 2021-2024 | Injectafer |
| Exact Sciences Corporation | $108.49 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $90.65 | 2023-2025 | Rexulti |
| Axonics, INC. | $83.41 | 2023 | Axonics |
| Intra-Sana Laboratories | $82.87 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Amarin Pharma, INC. | $81.10 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $76.12 | 2021 | |
| Radius Health, INC. | $76.12 | 2023-2025 | Tymlos |
| Astellas Pharma US INC | $74.58 | 2023-2024 | Veozah, Myrbetriq |
| Becton, Dickinson and Company | $71.48 | 2024 | Venclose Maven Catheter |
| Almatica Pharma LLC | $58.86 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $53.94 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $53.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $52.06 | 2022 | |
| Upsher-Smith Laboratories LLC | $48.40 | 2021-2022 | |
| Biomerieux INC | $45.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Kowa Pharmaceuticals America, INC. | $43.23 | 2021-2023 | Livalo, Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $42.44 | 2022 | |
| Arbor Pharmaceuticals, INC. | $42.18 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.76 | 2021-2025 | Xifaxan |
| Eisai INC. | $34.18 | 2021-2024 | |
| Mylan Specialty L.P. | $29.90 | 2023 | Yupelri |
| Sumitomo Pharma America, INC. | $23.31 | 2025 | Gemtesa |
| Si-Bone, INC. | $22.29 | 2023 | |
| Nestle Healthcare Nutrition INC. | $22.17 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.42 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $18.77 | 2025 | Inspire |
| Bausch Health US, LLC | $17.12 | 2022 | |
| Cequr Corporation | $17.06 | 2023 | Cequr Simplicity |
| Collegium Pharmaceutical, INC. | $16.64 | 2025 | Belbuca |
| Boston Scientific Corporation | $16.45 | 2023 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $16.35 | 2022 | |
| Seqirus USA INC | $16.04 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Edwards Lifesciences Corporation | $15.66 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Aytu Biopharma, INC. | $15.34 | 2021 | |
| Axsome Therapeutics, INC. | $14.23 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $13.91 | 2022 | |
| Neos Therapeutics, LP | $12.51 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.